Our Portfolio

Paradigm currently offers a comprehensive genomic profiling test for patients with advanced, refractory, or recurrent cancer, allowing physicians to better understand a patient’s tumor profile and more effectively recommend targeted therapies or clinical trials. Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies under its MolDx program, recently covered the test under its existing local coverage determination for Next-Generation Sequencing for Solid Tumors. Differentiated from other tests by a design that requires smaller sample requirements and delivers faster results, the test is critical in supporting treatment decisions and builds upon the successful foundation of the Exact Sciences’ Precision Oncology team.

March 3, 2020 /PRNewswire/ — (NASDAQ: EXAS) – Exact Sciences Corp. today announced the completion of its acquisition of Paradigm Diagnostics, Inc. a privately held company based in Phoenix. Paradigm provides a differentiated late-stage therapy selection test and deep competencies in sequencing and biomarker discovery, extending Exact Sciences’ lab testing and research and development capabilities.

The acquisition of Paradigm Diagnostics by Exact Sciences provided a positive return on investment to Desert Angels investors.